Drug

Cyclophosphamide

In clinical development

Emerging researchLate-stage developmentRising momentum

Also known as (RS)-Cyclophosphamide, Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester, CPM, CTX+11 more

(RS)-Cyclophosphamide, Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester, CPM, CTX, CYT, Ciclofosfamida, Ciclofosfamide, Cyclophosphanum, Cytophosphane, Cytoxan, Frindovyx, (+-)-Cyclophosphamide, Cyclophosphamid, Cyclophosphamidum, N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide.

RxNorm3002 ChEMBLCHEMBL1200796 ATCL01AA01UNII8N3DW7272P

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (CemiHALT )

Clinical trial2026-07-27Results posted · ClinicalTrials.gov

Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Clinical trial2026-07-24Status changed to Completed · ClinicalTrials.gov

A Phase I Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T- Cells for Treating B-cell Malignancies

Clinical trial2026-07-16Results expected Q4 2028 · ClinicalTrials.gov

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

Clinical trial2026-07-16Results expected Q3 2029 · ClinicalTrials.gov

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Clinical trial2026-07-16Results expected Q4 2026 · ClinicalTrials.gov

Phase I Trial of IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors

Clinical trial2026-07-10Results expected Q1 2028 · ClinicalTrials.gov

Administration of T Cells Expressing Chondroitin-Sulfate-Proteoglycan-4 Specific Chimeric Antigen Receptors (CAR) in Subjects With Head and Neck Squamous Cell Carcinoma (HNSCC)

Clinical trial2026-07-08Results expected Q3 2026 · ClinicalTrials.gov

A Phase Ib/II Study Evaluating the Safety and Efficacy of DA EPOCH in Combination With Mosuntuzumab (EPICSUN) in Previously Untreated C-Myc Rearrangement Positive High-Grade B Cell Lymphomas Including Myc Rearranged Diffuse Large B Cell Lymphoma and High Grade B Cell Lymphoma

Clinical trial2026-07-07Results expected Q4 2026 · ClinicalTrials.gov

CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.

Research2024-02-01The New England journal of medicine

Immune Enhancement of Clam Peptides on Immunosuppressed Mice Induced by Hydrocortisone.

Research2023-07-28Molecules (Basel, Switzerland)

Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data.

Research2022-11-16Arthritis care & research

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

Research2021-12-14The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Cyclophosphamide

Aliases & brands

(RS)-CyclophosphamideBis(2-chloroethyl)phosphoramide cyclic propanolamide esterCPMCTXCYTCiclofosfamidaCiclofosfamideCyclophosphanumCytophosphaneCytoxanFrindovyx(+-)-CyclophosphamideCyclophosphamidCyclophosphamidumN,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

RxNorm CUI

3002

ChEMBL ID

CHEMBL1200796

ATC codes

L01AA01

UNII

8N3DW7272P

Clinical trials

199 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

199

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 199

Early Phase 16Phase 146Phase 1 / 228Phase 275Phase 2 / 39Phase 328Phase 42Phase N / A5

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Prospective Randomized Study to Compare Efficacy and Safety of RFC-Lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status

TerminatedPH IVHoffmann-La Rochen=262016

German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2)

CompletedPH IVJohann Wolfgang Goethe University Hospitaln=602009

A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible

Active, not recruitingPH IIIStichting European Myeloma Networkn=7592040

A Randomized Phase III Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Participants With Previously Untreated Richter Transformation (PIRAMID)

Not yet recruitingPH IIISWOG Cancer Research Networkn=1022036

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Active, not recruitingPH IIIDana-Farber Cancer Instituten=5602034

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression

CompletedPH IISeagen, a wholly owned subsidiary of Pfizern=822026

Phase I-II Study of Escalating Doses of Large Field Image-Guided Intensity Modulated Radiation Therapy (IMRT) Using Helical Tomotherapy in Combination With Etoposide (VP16) and Cytoxan as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation for Patients With Poor Risk Acute Lymphocytic Leukemia (ALL) or Poor Risk Acute Myelogenous Leukemia (AML)

CompletedPH I/IICity of Hope Medical Centern=512026

Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer

CompletedPH IINational Cancer Institute (NCI)n=4542025

A Phase I/Ib Study of Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide and/or Bendamustine

CompletedPH IUniversity of Arizonan=502025

Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

CompletedPH IIDana-Farber Cancer Instituten=232024

A MULTICENTER, OPEN LABEL STUDY OF WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (wCCyd) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS

CompletedPH I/IIEuropean Myeloma Network B.V.n=632024

Research activity

24 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20012024

Most influential

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

The New England journal of medicine · 2005 · 3,717 cites

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

The Lancet. Oncology · 2019 · 1,761 cites

Cyclophosphamide versus placebo in scleroderma lung disease.

The New England journal of medicine · 2006 · 1,064 cites

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2008 · 1,043 cites

CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.

The New England journal of medicine · 2024 · 704 cites

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.

Journal of the National Cancer Institute. Monographs · 2001 · 696 cites

Related diseases

3 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Breast Neoplasms2 Lymphoma, Large B-Cell, Diffuse2 Scleroderma, Systemic2

Related drugs

8 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Doxorubicin

Studied across 15 of the same disease areas as Cyclophosphamide in the shared literature.

15 shared diseases5 shared papers

Fludarabine

Studied across 11 of the same disease areas as Cyclophosphamide in the shared literature.

11 shared diseases4 shared papers

Vidarabine

Studied across 11 of the same disease areas as Cyclophosphamide in the shared literature.

11 shared diseases4 shared papers

Prednisone

Studied across 10 of the same disease areas as Cyclophosphamide in the shared literature.

10 shared diseases2 shared papers

Vincristine

Studied across 9 of the same disease areas as Cyclophosphamide in the shared literature.

9 shared diseases2 shared papers

Bendamustine Hydrochloride

Studied across 8 of the same disease areas as Cyclophosphamide in the shared literature.

8 shared diseases1 shared paper

Paclitaxel

Studied across 8 of the same disease areas as Cyclophosphamide in the shared literature.

8 shared diseases1 shared paper

Cisplatin

Studied across 5 of the same disease areas as Cyclophosphamide in the shared literature.

5 shared diseases1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials